David J. Behm - Concepedia

Author

David J. Behm

GlaxoSmithKline (United States)

Also Known As

Behm, David J., D BEHM, D Behm, D J Behm, D. Behm, D. J. Behm, D. Johannes Behm, D.J. Behm, David Behm, David J Behm

Publications

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Pathways Behavioral Services South College Research Triangle Park Foundation

About

David J. Behm is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	25	1.2K
2	Biochemistry	9	9	619
3	Natural Sciences	5	5	310
4	Cell Biology	2	2	80
5	Health Sciences	1	1	41

David J. Behm

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2 Robert N. Willette, Weike Bao, Sandhya S. Nerurkar, Journal of Pharmacology and Experimental Therapeutics	2008	291
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects David G. Johns, David J. Behm, Deborah J. Walker, British Journal of Pharmacology	2007	241
Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities Chris P. Doe, Ross Bentley, David J. Behm, Journal of Pharmacology and Experimental Therapeutics	2006	156
Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors Krista Goodman, Haifeng Cui, Sarah E. Dowdell, Journal of Medicinal Chemistry Indazole SubstitutionMedicinal ChemistryOral BioavailabilityRho KinaseMedicine	2006	154
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor Patricia L. Podolin, Brian Bolognese, Joseph Foley, Prostaglandins & Other Lipid Mediators Molecular PharmacologyOxysterolBiochemistryMedicineLipid Peroxidation	2013	110
Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation David J. Behm, Andrea C. Ogbonna, Charlene Wu, Journal of Pharmacology and Experimental Therapeutics	2008	101
Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production Weike Bao, David J. Behm, Sandhya S. Nerurkar, Journal of Cardiovascular Pharmacology HypertensionCardiovascular PharmacologyP38 MapkPharmacotherapyAng Ii	2007	98
Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat Weike Bao, Pu Qin, Saul Needle, Journal of Cardiovascular Pharmacology	2010	98
Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4 Mui Cheung, Weike Bao, David J. Behm, ACS Medicinal Chemistry Letters	2017	94
Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases Clark A. Sehon, Gren Z. Wang, Andrew Q. Viet, Journal of Medicinal Chemistry Medicinal ChemistryPotential Therapeutic AgentsBiochemistryRho KinaseMedicine	2008	72

Page 1